Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to tame Cushing's disease with fewer side effects

NCT ID NCT07603466

Disease control Sponsor: University of Basrah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding cabergoline to osilodrostat works better than osilodrostat alone for controlling Cushing's disease. About 50 adults with active Cushing's disease will receive either the combination or the single drug. The goal is to see if the combo can lower cortisol faster, reduce the needed dose of osilodrostat, and lessen side effects like high blood pressure and hormone imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cushing's disease: Not treated or received treatment (TSS and/or radio surgery). And * Active disease confirmed with repeated two biochemical tests (1-mg overnight dexamethasone suppression test and late night salivary cortisol), And * Inappropriate ACTH elevation, And * Positive ACTH response to desmopressin stimulation test, And * MRI finding of pituitary adenoma. Exclusion Criteria: * Severe hepatic impairment (Child-Pugh C). * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cushing disease due to increased ACTH secretion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ACTH-dependent Cushing syndrome adrenocortical insufficiency Cushing disease due to pituitary adenoma Hyperandrogenism hypertensive disorder potassium deficiency disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cushing disease due to increased ACTH secretion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Al-Hassan Metabolism Endocrine and Diabetes Center

    Karbala, Iraq

  • Al-Waffa Specialized Center for Diabetes and Endocrinology

    Mosul, Iraq

  • Faiha Specialized Diabetes, Endocrine, and Metabolism Center

    Basra, 61001, Iraq

  • Najaf Specialized Diabetes and Endocrine Center

    Najaf, Iraq

  • Thi-Qar Specialized Diabetes, Endocrine and Metabolism Center

    Nasiriyah, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.